CHADS2VASc Calculator (CHA2DS2‑VASc)

Fill in the patient information. The CHA2DS2‑VASc score will be calculated to estimate stroke risk in atrial fibrillation.

1
Basic information

Age *

Select an age range and the score will be calculated automatically.

Sex

Male0

Female+1

2
Medical conditions

Hypertension

SBP ≥ 140 mmHg or DBP ≥ 90 mmHg

Heart failure

LV dysfunction or history of HF

Diabetes

FPG ≥ 7.0 mmol/L or HbA1c ≥ 6.5%

Stroke/TIA history

Prior stroke or transient ischemic attack

Vascular disease

MI, PAD, or aortic plaque

10 people found this calculator helpful

Awaiting result

Enter patient information and click calculate

Why choose our CHADS2VASc Calculator?

Built on international standards to support clinical decision‑making

🎯

Evidence-based

Built on the widely accepted CHA2DS2‑VASc (chads2vasc) scoring system

⚡

Instant results

Real‑time chads2vasc calculation with personalized guidance

🔒

Privacy‑friendly

All calculations run locally; no personal data stored

📱

Responsive design

Works beautifully on desktop, tablet and mobile

👨‍⚕️

Trusted by clinicians

A reliable CHADS2VASc risk tool for clinicians and patients

💡

Easy to use

Clean, intuitive interface for a smooth experience

How the score works

Understand the evidence behind CHA2DS2‑VASc

1What is the CHA2DS2‑VASc score?

The CHA2DS2‑VASc score is an internationally accepted tool to estimate stroke risk in patients with atrial fibrillation. It considers several key clinical factors to support treatment decisions.

Scoring factors:

CCongestive heart failure

HHypertension

AAge

DDiabetes

SStroke/TIA history

VVascular disease

AAge

SSex (female)

2Scoring rules

Age:

≥75 years+2

65–74 years+1

<65 years0

Other factors:

Female sex+1

Hypertension+1

Heart failure+1

Diabetes+1

Stroke/TIA history+2

Vascular disease+1

Facts & data

The table shows the relationship between CHA2DS2‑VASc scores and annual event risk

CHA2DS2‑VASc score	Ischemic stroke risk	Stroke/TIA/systemic embolism
0	0.2%	0.3%
1	0.6%	0.9%
2	2.2%	2.9%
3	3.2%	4.6%
4	4.8%	6.7%
5	7.2%	10.0%
6	9.7%	13.6%
7	11.2%	15.7%
8	10.8%	15.2%
9	12.2%	17.4%

Source:Friberg, 2012. Note: risk appears paradoxically lower at 7–8 in this dataset; typically higher scores imply higher risk.

Chart

Evidence summary

CHA2DS2‑VASc is an update to the older CHADS₂ score to provide a simple clinical tool for predicting 1‑year thromboembolic risk in non‑valvular AF. Despite limitations in the derivation cohorts, the score has been validated across regions and is clinically useful. While overall discrimination is modest (c‑statistic ~0.6–0.7), the negative predictive value for truly low‑risk patients is high, helping identify those who may not require anticoagulation.

As a result, CHA2DS2‑VASc is widely validated and incorporated into international guidelines as a core index for AF risk stratification. Although explored in other populations, routine use is focused on its original purpose in AF.

Since 2010, AF epidemiology and management have evolved. The role of sex has been debated; recent guidance (e.g., 2024 ESC) discusses CHA2DS2‑VA (sex removed), harmonizing anticoagulation thresholds and inclusivity. Some cohorts show similar or slightly improved performance with CHA2DS2‑VA.

Additional refinements have been proposed (e.g., incorporating cancer) but require further validation.

In summary, CHA2DS2‑VASc remains central to AF stroke risk assessment, and ongoing refinements will continue as clinical practice evolves.

More details and references:MDCalc evidence page.

FAQ

Common questions about the CHA2DS2‑VASc score

What is the CHA2DS2‑VASc score?

An internationally accepted score to estimate ischemic stroke risk in atrial fibrillation. It considers age, sex, heart failure, hypertension, diabetes, prior stroke/TIA, and vascular disease.

Who should be assessed with CHA2DS2‑VASc?

Primarily adults with atrial fibrillation. The score helps clinicians estimate stroke risk in atrial fibrillation and guide anticoagulation decisions.

How do I interpret results?

Scores range 0–9. 0: low risk (typically no anticoagulation). 1: low–moderate (individual assessment). ≥2: moderate/high (anticoagulation usually recommended). Decisions are clinician‑led.

How is age counted?

≥75 years: +2; 65–74 years: +1; <65 years: 0.

How does sex affect the score?

Female sex adds +1; male adds 0.

What counts as vascular disease?

Myocardial infarction, peripheral arterial disease, or aortic plaque (adds +1).

Does this replace medical advice?

No. It is a decision‑support tool and not a substitute for professional diagnosis or treatment.

How often should I reassess?

Reassess periodically, especially when clinical status changes (new conditions, aging, etc.).

Important notice

This tool is for education only and does not replace clinical judgment. Consult a qualified clinician for diagnosis and treatment.

Evidence & references

Derived from peer‑reviewed studies and clinical guidelines

📚Key studies

Development and validation of CHA2DS2‑VASc

Lip GYH, et al.

Chest, 2010

Original proposal of CHA2DS2‑VASc and validation of stroke risk prediction in AF.

European Society of Cardiology AF guidelines

ESC Guidelines

European Heart Journal, 2020

Guidelines recommending CHA2DS2‑VASc for stroke risk assessment with treatment guidance.

Validation of CHA2DS2‑VASc in diverse populations

Olesen JB, et al.

BMJ, 2011

Validated predictive accuracy of CHA2DS2‑VASc in a nationwide Danish cohort.

Validation of CHA2DS2‑VASc in Asian populations

Chao TF, et al.

Journal of the American College of Cardiology, 2015

Confirmed applicability and performance in Asian AF cohorts.

📋Clinical guidelines & recommendations

ACC/AHA guidelines

ACC/AHA(2019)

Recommend CHA2DS2‑VASc for AF stroke risk assessment and anticoagulation strategy.

Canadian Cardiovascular Society guidelines

CCS(2020)

Emphasize CHA2DS2‑VASc in AF management with detailed application guidance.

Asia Pacific Society of Cardiology consensus

APSC(2017)

Regional recommendations for CHA2DS2‑VASc use in APAC AF populations.

World Heart Federation statement

WHF(2021)

Highlights standardized global use of CHA2DS2‑VASc in AF management.

Academic note

This calculator is developed from the literature and guidelines listed above and is updated periodically.

Start your assessment

Use the CHA2DS2‑VASc score to inform clinical decision‑making